Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Income from Continuing Operations (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Income from Continuing Operations for 11 consecutive years, with 1998662.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 13.41% to 1998662.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 14365524.0, a 817.12% decrease, with the full-year FY2024 number at 10731315.0, up 23.6% from a year prior.
  • Income from Continuing Operations was 1998662.0 for Q3 2025 at Marker Therapeutics, up from 4133008.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 8896926.0 in Q4 2023 to a low of 10906782.0 in Q2 2021.
  • A 5-year average of 4414535.05 and a median of 4098980.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 403.73% in 2023; the steepest drop was 274.22% in 2023.
  • Marker Therapeutics' Income from Continuing Operations stood at 9763316.0 in 2021, then skyrocketed by 70.0% to 2929258.0 in 2022, then skyrocketed by 403.73% to 8896926.0 in 2023, then plummeted by 142.57% to 3787670.0 in 2024, then soared by 47.23% to 1998662.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Income from Continuing Operations are 1998662.0 (Q3 2025), 4133008.0 (Q2 2025), and 4446184.0 (Q1 2025).